HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Raises Price Target to $60

Benzinga · 1d ago
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $46 to $60.